Trial reportBone marrow transplantation2012
Autologous platelet lysate for treatment of refractory ocular GVHD.
Trial report in Bone marrow transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Finger-Prick Autologous Blood (FAB) Eye Drops for Dry Eye Disease: Single Masked Multi-Centre Randomised Controlled Trial.Clinical ophthalmology (Auckland, N.Z.) · 2022Trial
- Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD.Bone marrow transplantation · 2017Trial
- Subconjunctival injectable platelet-rich fibrin for severe dry eye disease: Preliminary clinical results.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Blood Derivatives in the Therapy of Ocular Surface Diseases.International journal of molecular sciences · 2025Review
- Allogeneic fresh frozen plasma eye drops for the treatment of ocular Graft-versus-Host disease: prospective open-label study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- A brief account on ocular graft versus host disease.Indian journal of ophthalmology · 2023Review
- Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.Frontiers in medicine · 2023Review
- Autologous Platelet-Rich Plasma Drops for Evaporative Dry Eye Disease from Meibomian Gland Dysfunction: A Pilot Study.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Update on ocular graft-versus-host disease.Indian journal of ophthalmology · 2021Review
- Platelet lysate for COVID-19 pneumonia-a newer adjunctive therapeutic avenue.Stem cell investigation · 2021Review
- Human Platelets and Derived Products in Treating Ocular Surface Diseases - A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.Journal of clinical medicine · 2019Review
- Comparative Analysis of Different Platelet Lysates and Platelet Rich Preparations to Stimulate Tendon Cell Biology: An In Vitro Study.International journal of molecular sciences · 2018Article
- Application of Novel Drugs for Corneal Cell Regeneration.Journal of ophthalmology · 2018Review
- The Effect of Autologous Platelet Lysate Eye Drops: An In Vivo Confocal Microscopy Study.BioMed research international · 2016Article
- Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations.Journal of ophthalmic & vision research · 2013Review
- Effectiveness of oral platelet lysate gel to treat oral mucosal manifestations associated with chronic graft versus host disease.Blood transfusion = Trasfusione del sangueObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current treatment of ocular GVHD (oGVHD), represented by systemic immunosuppressive regimens and local therapies (mainly artificial tears and corticosteroids), gives unsatisfactory results. We investigated the safety and efficacy of autologous plasma rich in PDGFs to treat oGVHD unresponsive to standard medications. A total of 23 patients with refractory oGVHD (grade II-IV) unresponsive to standard therapy were treated with autologous plasma rich in PDGFs eye drops (PRGD) four times/day for 6 months. Symptoms and signs (best visual acuity, Schirmer's test and tear break up time (TBUT), evaluation of the anterior segment and fluorescein and lissamine staining) were always assessed by the same ophthalmologist. Patients were defined as 'responders' when showing improvement for total complaints and at least one sign. At 30 days of treatment, 17 patients (73.9%) were classified as responders. The symptom that improved most was photophobia (improved in 19 patients, 82.6%). TBUT improved in 20 patients (86.9%) and anterior segment score in 19 patients (82.6%). Response was maintained over time. No serious adverse events occurred. PRGD proved to be safe and effective in treating oGVHD and may be a valid treatment option from the early stages of the disease to avoid irreversible ocular damage.
Indexed as
Identifiers
22522569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.